Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312505 | 1.00 | CTSK (0.49) | CTSKMAPK1MMP2MMP9CACNA1B | |
| SCHEMBL4315414 | 1.00 | CTSK (0.49) | CTSKMAPK1MMP2MMP9CACNA1B | |
| SCHEMBL4312501 | 1.00 | CTSK (0.49) | CTSKMAPK1MMP2MMP9CACNA1B | |
| SCHEMBL13784250 | 0.89 | CTSK (0.52) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13784253 | 0.89 | CTSK (0.52) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6212545 | 0.89 | CTSK (0.48) | CTSKMMP2CACNA1BCTSLCTSS | |
| SCHEMBL6212535 | 0.89 | CTSK (0.48) | CTSKMMP2CACNA1BCTSLCTSS | |
| SCHEMBL6242261 | 0.89 | CTSK (0.48) | CTSKMMP2CACNA1BCTSLCTSS | |
| SCHEMBL6242254 | 0.89 | CTSK (0.48) | CTSKMMP2CACNA1BCTSLCTSS | |
| SCHEMBL7036592 | 0.85 | CTSK (0.51) | CTSKMAPK1CACNA1BCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSK 1/4885MAPK1 2421/4885MMP2 30/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885MAPK1 2113/4885MMP2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.